IP Library Granted Patent US 10,945,420
Granted Patent B2
US 10,945,420 · App. 16/436,805 · Granted Mar 16, 2021

Genetically modified non-human animal with human or chimeric CD3e

Inventors: Yuelei Shen (Beijing, CN); Yanan Guo (Beijing, CN); Rui Huang (Beijing, CN); Xiaofei Zhou (Beijing, CN); Yang Bai (Beijing, CN); Jiawei Yao (Beijing, CN); Chaoshe Guo (Beijing, CN)
Assignees: BiocytogenPharmaceuticals (Beijing) Co., Ltd.; Biocytogen JiangSu Co., Ltd.
A01K67/0278A61K35/51A61K49/0008A01K2207/15A01K2227/105A01K2267/0331
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,945,420
App. No.
16/436,805
Granted
Mar 16, 2021
Kind
B2
Abstract

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD3e (T-cell surface glycoprotein CD3 epsilon chain), and methods of use thereof.

Claims (18)

1. A genetically-modified, non-human mammal whose genome comprises a replacement of a nucleic acid sequence encoding a portion of the extracellular region of an endogenous CD3e with a nucleic acid sequence encoding the corresponding portion of the extracellular region of a human CD3e, wherein the replacement results in a sequence encoding a chimeric CD3e comprising an amino acid sequence that is at least 95% identical to amino adds 1-126 of SEQ ID NO: 7, at an endogenous CD3e gene locus, wherein the chimeric CD3e associates with endogenous CD3γ and endogenous CD3δ, forming a functional CD3 complex in the mammal, wherein the non-human mammal detectably expresses the chimeric CD3e on the surface of one or more activated T cells.

2. The mammal of claim 1 , wherein the sequence encoding the chimeric CD3e is operably linked to an endogenous regulatory element at the endogenous CD3e gene locus in the at least one chromosome.

3. The mammal of claim 1 , wherein the chimeric CD3e comprises the amino acid sequence of SEQ ID NO: 10.

4. The mammal of claim 1 , wherein the mammal is a rodent.

5. The mammal of claim 1 , wherein the mammal is a mouse.

6. The mammal of claim 1 , wherein the mammal does not express endogenous CD3e.

7. The mammal of claim 1 , wherein the mammal further comprises a sequence encoding an additional human or chimeric protein.

8. The mammal of claim 7 , wherein the additional human or chimeric protein is programmed cell death protein 1 (PD-1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Lymphocyte Activating 3 (LAG-3), B And T Lymphocyte Associated (BTLA), Programmed Cell Death 1 Ligand 1 (PD-L1), CD27, CD28, CD47, CD137, CD154, T-Cell Immunoreceptor With Ig And ITIM Domains (TIGIT), T-cell Immunoglobulin and Mucin-Domain Containing-3 (TIM-3), Glucocorticoid-Induced TNFR-Related Protein (GITR), TNF Receptor Superfamily Member 4 (OX40), CD3δ, CD3γ, CD40, or CD278.

9. The mammal of claim 1 , wherein the chimeric CD3e comprises a human signal peptide.

10. The mammal of claim 1 , wherein the expressed chimeric CD3e can be recognized by an anti-human CD3e antibody or antigen-binding fragment thereof.

11. The mammal of claim 1 , wherein the mammal is homozygous with respect to the sequence encoding the chimeric CD3e at the endogenous CD3e locus.

12. The mammal of claim 1 , wherein the chimeric CD3e consists of the amino acid sequence of SEQ ID NO: 10.

13. The mammal of claim 1 , wherein the chimeric CD3e comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 10.

14. A genetically-modified, non-human mammal whose genome comprises a replacement of a nucleic acid sequence encoding the extracellular region of an endogenous CD3e with a nucleic acid sequence encoding the corresponding extracellular region of a human CD3e, wherein the replacement results in a sequence encoding a chimeric CD3e comprising an amino acid sequence that is at least 95% identical to amino acids 1-126 of SEQ ID NO: 7, at an endogenous CD3e gene locus, wherein the chimeric CD3e associates with endogenous CD3γ and endogenous CD3δ, forming a functional CD3 complex in the mammal, wherein the non-human mammal detectably expresses the chimeric CD3e on the surface of one or more activated T cells.

15. The mammal of claim 14 , wherein the sequence encoding the chimeric CD3e is operably linked to an endogenous regulatory element at the endogenous CD3e gene locus in the at least one chromosome.

16. A genetically-modified, non-human mammal whose genome comprises a replacement of a nucleic acid sequence encoding an endogenous CD3e with a corresponding nucleic acid sequence encoding a human CD3e, wherein the replacement results in a sequence encoding a chimeric CD3e comprising an amino acid sequence that is at least 95% identical to amino acids 1-126 of SEQ ID NO: 7, at an endogenous CD3e gene locus, wherein the human CD3e associates with endogenous CD3γ and endogenous CD3 δ, forming a functional CD3 complex in the mammal, wherein the non-human mammal detectably expresses the human CD3e on the surface of one or more activated T cells.

17. The mammal of claim 16 , wherein the sequence encoding the human CD3e is operably linked to an endogenous regulatory element at the endogenous CD3e gene locus in the at least one chromosome.

18. The mammal of claim 14 , wherein the mammal is a mouse.

Assignments (2)
CHANGE OF NAME Recorded Jan 22, 2021
From: BEIJING BIOCYTOGEN CO., LTD
To: BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Reel/Frame 055087/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2019
From: SHEN, YUELEI; GUO, YANAN; HUANG, RUI; ZHOU, XIAOFEI; BAI, YANG; YAO, JIAWEI; GUO, CHAOSHE
To: BEIJING BIOCYTOGEN CO., LTD.; BIOCYTOGEN JIANGSU CO.,LTD.
Reel/Frame 050433/0145 →
Priority Claims (3)
CN 201711316875.2 · Dec 12, 2017 · national
CN 201810434327.8 · May 8, 2018 · national
CN 201811255583.7 · Oct 26, 2018 · national
Continuity (2)
Continuation PCTCN2018120713 · Dec 12, 2018
Related Publication 20190373869A1 · Dec 12, 2019